TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences

Reuters

2025/10/08

TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences

TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573092844"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573092844\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573092844?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573092844","market":"fut","top_or_hot":-1,"title":"TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1569","symbol_name":"长和系","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL7rMKPn:1","article_id":"2573092844","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573092844","pubTimestamp":1759924947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.Disclaimer: This news brief was created by Public Technologies  using generative ar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1569":"长和系","00775":"长江生命科技","BK4139":"生物科技","RNAZ":"TransCode Therapeutics  Inc.","BK1161":"生物科技","BK4539":"次新股"},"translate_title":"TransCode Therapeutics收购Polynoma获长江生命科技2500万投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00775":0.9,"RNAZ":0.9},"content_text":"TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences\n    \n\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}